Kymera Therapeutics Presents Phase 1b Data for KT-621 at AAD Meeting

Kymera Therapeutics, Inc. (NASDAQ: KYMR) presented new clinical data for KT-621, its investigational oral therapy for inflammatory diseases, during the American Academy of Dermatology (AAD) Annual Meeting. The results come from the BroADen Phase 1b trial evaluating the drug in patients with moderate-to-severe atopic dermatitis.

KT-621 is designed as a first-in-class oral STAT6 degrader, targeting a key protein that drives Type 2 inflammatory diseases such as eczema and asthma.

Phase 1b trial shows strong biomarker and clinical activity

Results from the BroADen Phase 1b study demonstrated strong biological activity and promising clinical improvements. The therapy achieved deep degradation of the STAT6 protein, with reductions of approximately 94% to 98% in both blood and skin samples.

Additional findings from the trial included:

• Significant reductions in Type 2 inflammatory biomarkers such as TARC and Eotaxin-3
• Rapid onset of activity, with measurable improvements by Day 8
• Approximately 63% average reduction in EASI scores, a key measure used to assess eczema severity

The results suggest that KT-621 may offer meaningful clinical benefits for patients with moderate-to-severe atopic dermatitis.

Favorable safety profile observed

KT-621 was generally well tolerated during the Phase 1b trial. No serious adverse events were reported, and the safety profile appeared comparable to placebo in earlier clinical evaluations.

The BroADen trial enrolled 22 patients who received once-daily dosing for 28 days followed by a monitoring period.

Potential oral alternative to injectable biologics

KT-621 is being developed as an oral alternative to injectable biologic treatments currently used for inflammatory diseases. Many leading therapies for atopic dermatitis, such as Dupixent, marketed by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY), require injections.

If successful, an effective oral therapy could offer a more convenient treatment option for patients managing chronic inflammatory conditions.

Next steps in clinical development

Kymera Therapeutics is advancing KT-621 into larger clinical studies. The company has already initiated a Phase 2b trial in atopic dermatitis, with results expected around mid-2027. A Phase 2b trial evaluating the drug in eosinophilic asthma is also expected to begin in 2026.

Investor perspective

The new data highlight the potential of Kymera’s targeted protein degradation platform, which focuses on selectively eliminating disease-causing proteins rather than simply blocking their activity.

If future clinical trials confirm these results, KT-621 could become a competitive treatment in the rapidly expanding market for Type 2 inflammatory diseases.

Bottom line

The Phase 1b results presented at the AAD meeting demonstrate encouraging clinical activity for KT-621 in patients with atopic dermatitis. With strong biomarker reductions and a favorable safety profile, Kymera Therapeutics is advancing the program into later-stage trials that could position the drug as a potential oral alternative to existing biologic treatments.